SIRT1 activation by methylene blue, a repurposed drug, leads to AMPK-mediated inhibition of steatosis and steatohepatitis

European Journal of Pharmacology

Volumn 727, Issue 1, 2014, Pages 115-124

  Shin, Seo Young ^a   Kim, Tae Hyun ^a   Wu, Hongmin ^a   Choi, Young Hee ^b   Kim, Sang Geon ^a  

^a Seoul National University   (South Korea)

^b Dongguk University   (South Korea)

Author keywords

Lipogenesis; Methylene blue; Mitochondria; SIRT1; Steatoheptitis

Indexed keywords

ENZYME ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METHYLENE BLUE; MITOCHONDRIAL DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRT1 PROTEIN, HUMAN; SIRT1 PROTEIN, MOUSE; SIRTUIN 1;

ANIMAL; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG REPOSITIONING; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYMOLOGY; FATTY LIVER; GENETIC TRANSFECTION; GENETICS; HEPG2 CELL LINE; HUMAN; LIPID METABOLISM; LIVER; LIVER MITOCHONDRION; MALE; METABOLISM; MITOCHONDRIAL DYNAMICS; ORAL DRUG ADMINISTRATION; PATHOLOGY; RAT; RNA INTERFERENCE; TIME;

ADMINISTRATION, ORAL; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG REPOSITIONING; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVATORS; FATTY LIVER; HEP G2 CELLS; HUMANS; LIPID METABOLISM; LIVER; MALE; METHYLENE BLUE; MICE, INBRED C57BL; MITOCHONDRIA, LIVER; MITOCHONDRIAL TURNOVER; NAD; RATS; RNA INTERFERENCE; SIRTUIN 1; TIME FACTORS; TRANSFECTION;

EID: 84893697774     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.01.035     Document Type: Article

References (34)

1. Z. Arany, H. He, J. Lin, K. Hoyer, C. Handschin, O. Toka, F. Ahmad, T. Matsui, S. Chin, P.H. Wu, I.I. Rybkin, J.M. Shelton, M. Manieri, S. Cinti, F.J. Schoen, R. Bassel-Duby, A. Rosenzweig, J.S. Ingwall, and B.M. Spiegelman Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle Cell Metabol. 1 2005 259 271
2. H. Atamna, A. Nguyen, C. Schultz, K. Boyle, J. Newberry, H. Kato, and B.N. Ames Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways FASEB J. 22 2008 703 712
3. H. Atamna, J. Mackey, and J.M. Dhahbi Mitochondrial pharmacology: electron transport chain bypass as strategies to treat mitochondrial dysfunction Biofactors 38 2012 158 166
4. A. Brunet, L.B. Sweeney, J.F. Sturgill, K.F. Chua, P.L. Greer, Y. Lin, H. Tran, S.E. Ross, R. Mostoslavsky, H.Y. Cohen, L.S. Hu, H.L. Cheng, M.P. Jedrychowski, S.P. Gygi, D.A. Sinclair, F.W. Alt, and M.E. Greenberg Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase Science 303 2004 2011 2015
5. N.L. Callaway, P.D. Riha, K.M. Wrubel, D. McCollum, and F. Gonzalez-Lima Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats Neurosci. Lett. 332 2002 83 86
6. Y.H. Choi, U. Lee, J.H. Suh, Y.G. Kim, E.Y. Choi, E. Oh, and M.G. Lee Pharmacokinetics and first-pass effects of ε-acetamidocaproic acid after administration of zinc acexamate in rats Xenobiotica 40 2010 485 498
7. M.A. Cornier, D. Dabelea, T.L. Hernandez, R.C. Lindstrom, A.J. Steig, N.R. Stob, R.E. Van Pelt, H. Wang, and R.H. Eckel The metabolic syndrome Endocr. Rev. 29 2008 777 822
8. G.P. Eckert, K. Renner, S.H. Eckert, J. Eckmann, S. Hagl, R.M. Abdel-Kader, C. Kurz, K. Leuner, and W.E. Muller Mitochondrial dysfunction-a pharmacological target in Alzheimer S disease Mol. Neurobiol. 46 2012 136 150
9. E. Fabbrini, S. Sullivan, and S. Klein Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications Hepatology 51 2010 679 689
10. C. Frezza, S. Cipolat, and L. Scorrano Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts Nat. Protoc. 2 2007 287 295
11. N.F. Gaudette, and J.W. Lodge Determination of methylene blue and leucomethylene blue in male and female Fischer 344 rat urine and B6C3F1 mouse urine J. Anal. Toxicol. 29 2005 28 33
12. M. Gibaldi, and D. Perrier Pharmacokineics 2nd ed. 1982 Marcel-Dekker New York
13. C.Y. Han, S.H. Ki, Y.W. Kim, K. Noh, Y. Lee, da., B. Kang, J.H. Ryu, R. Jeon, E.H. Kim, S.J. Hwang, and S.G. Kim Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activation Antioxid. Redox Signal. 14 2011 187 202
14. S.Y. Han, Y-W. Chin, and Y.H. Choi A new approach for pharmacokinetic studies of natural products: measurement of isoliquiritigenin levels in mice plasma, urine and feces using modified automated dosing/blood sampling system Biomed. Chromatogr. 27 2013 741 749
15. S.H. Hwahng, S.H. Ki, E.J. Bae, H.E. Kim, and S.G. Kim Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones Hepatology 49 2009 1913 1925
16. B.P. Hubbard, A.P. Gomes, H. Dai, J. Li, A.W. Case, T. Considine, T.V. Riera, J.E. Lee, D.W. Lamming, B.L. Pentelute, E.R. Schuman, L.A. Stevens, A.J. Ling, S.M. Armour, S. Michan, H. Zhao, Y. Jiang, S.M. Sweitzer, C.A. Blum, J.S. Disch, P.Y. Ng, K.T. Howitz, A.P. Rolo, Y. Hamuro, J. Moss, R.B. Perni, J.L. Ellis, G.P. Vlasuk, and D.A. Sinclair Evidence for a common mechanism of SIRT1 regulation by allosteric activators Science 339 2013 1216 1219
17. T.H. Kim, J.S. Eom, C.G. Lee, Y.M. Yang, Y.S. Lee, and S.G. Kim An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK British J. Pharmacol. 168 2013 1647 1661
18. T.R. Koves, J.R. Ussher, R.C. Noland, D. Slentz, M. Mosedale, O. Ilkayeva, J. Bain, R. Stevens, J.R. Dyck, C.B. Newgard, G.D. Lopaschuk, and D.M. Muoio Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance Cell Metabol. 7 2008 45 56
19. M. Lagouge, C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N. Messadeq, J. Milne, P. Lambert, P. Elliott, B. Geny, M. Laakso, P. Puigserver, and J. Auwerx Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha Cell 127 2006 1109 1122
20. M. Lakshminarasimhan, D. Rauh, M. Schutkowski, and C. Steegborn Sirt1 activation by resveratrol is substrate sequence-selective Aging (Albany NY) 5 2013 151 154
21. F. Lan, J.M. Cacicedo, N. Ruderman, and Y. Ido SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation J. Biol. Chem. 283 2008 27628 27635
22. M.G. Lee, and W.L. Chiou Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism J. Pharmacokinet. Biopharm. 11 1983 623 660
23. S.K. Mantena, A.L. King, K.K. Andringa, H.B. Eccleston, and S.M. Bailey Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases Free Radic. Biol. Med. 44 2008 1259 1272
24. S.K. Mantena, D.P. Vaughn, K.K. Andringa, H.B. Eccleston, A.L. King, G.A. Abrams, J.E. Doeller, D.W. Kraus, V.M. Darley-Usmar, and S.M. Bailey High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo Biochem. J. 417 2009 183 193
25. F. Marra, A. Gastaldelli, G. Svegliati Baroni, G. Tell, and C. Tiribelli Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis Trends Mol. Med. 14 2008 72 81
26. G. Musso, R. Gambino, F. De Michieli, M. Cassader, M. Rizzetto, M. Durazzo, E. Fagà, B. Silli, and G. Pagano Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis Hepatology 37 2003 909 916
27. N. Nasrin, X. Wu, E. Fortier, Y. Feng, O.C. Bare S. Chen, X. Ren, Z. Wu, R.S. Streeper, and L Bordone SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells J. Biol. Chem. 285 2010 31995 32002
28. J.M. Orellana-Gavaldà, L. Herrero, M.I. Malandrino, A. Pañeda, M. Sol Rodríguez-Peña, H. Petry, G. Asins, S. Van Deventer, F.G. Hegardt, and D. Serra Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation Hepatology 53 2011 821 832
29. D. Pessayre, and B. Fromenty NASH: a mitochondrial disease J. Hepatol. 42 2005 928 940
30. A. Purushotham, T.T. Schug, Q. Xu, S. Surapureddi, X. Guo, and X. Li Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation Cell Metabol. 9 2009 327 338
31. J.T. Rodgers, C. Lerin, Z. Gerhart-Hines, and P. Puigserver Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways FEBS Lett. 582 2008 46 53
32. S.S. Singh Preclinical pharmacokinetics: an approach towards safer and efficacious drugs Curr. Drug Metabol. 7 2006 165 182
33. Y. Wen, W. Li, E.C. Poteet, L. Xie, C. Tan, L.J. Yan, X. Ju, R. Liu, H. Qian, M.A. Marvin, M.S. Goldberg, H. She, Z. Mao, J.W. Simpkins, and S.H. Yang Alternative mitochondrial electron transfer as a novel strategy for neuroprotection J. Biol. Chem. 286 2011 16504 16515
34. M. Yoon The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions Pharmacol. Res. 60 2009 151 159